Sarici, AhmetTanriverdi, Lokman H.Hernandez, Adrian, VAltuntas, FevziSaglio, Giuseppe2026-04-042026-04-0420250006-49711528-0020https://doi.org/10.1182/blood-2025-7298https://hdl.handle.net/11616/10899067th Annual Meeting of the American-Society-of-Hematology (ASH) -- DEC 06-09, 2025 -- Orlando, FL[No abstract available]eninfo:eu-repo/semantics/openAccessChronic myeloid leukemiaAsciminibTyrosine kinase inhibitorsMajor molecular responsegrade >3 adverse eventsAsciminib in chronic myeloid leukemia: Superior efficacy and favorable safety outcomes from a systematic review and meta-analysisConference Object1467298729810.1182/blood-2025-7298WOS:001669688500048Q1